The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Abstract
Bone is the primary anatomical site of breast cancer metastasis, and bone metastasis is associated with increased morbidity and mortality. Mesenchy‐mal stem cells (MSC) are a predominant fibroblast cell population within the bone marrow, and metastatic breast cancer cells that seed within bone would predictably encounter MSC or their soluble factors. Therefore, we examined the impact of primary human MSC on a panel of estrogen receptor‐alpha (ERα)‐positive (MCF‐7, T47D, BT474, and ZR‐75–1) and ERα‐negative (MDA‐MB‐231 and MDA‐MB‐468) human breast tumor cell lines. All ERα‐positive breast tumor cell lines displayed low basal activation of signal transducer and activator of transcription 3 (STAT3) until exposed to MSC, which induced chronic phosphorylation of STAT3 on tyrosine‐705. Paracrine IL‐6 was found to be the principal mediator of STAT3 phosphorylation in coculture studies, and MSC induction of STAT3 phos‐phorylation was lost when IL‐6 was depleted from MSC conditioned media or the IL‐6 receptor was blocked on tumor cells. Enhanced tumor cell growth rates were observed in the ERα‐positive mammary tumor cell line MCF‐7 after paracrine and autocrine IL‐6 exposure, where MCF‐7 growth rates were enhanced by > 2‐fold when cocultured with MSC in vitro and even more pronounced in vivo with autocrine IL‐6 production.—Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., Hall, B. M. Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer. FASEB J. 21, 3763–3770 (2007)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-6 is an MSC-secreted inflammatory cytokine displaying pro-survival, pro-growth and pro-angiogenic activities [11], which has been implicated in tumor progression of various cancers including breast cancer [113, 114].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [113]
In the citing paper
“The production of trophic factors from MSCs including VEGF, chemokine CCL5 and IL6 (activation STAT-3) has been connected with tumour growth and metastasis in Burkitt's lymphoma, breast cancer, colonic cancer and chronic myeloid leukaemia [69], [70], [71], [72], [73].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [70]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“Mesenchymal stem cells (MSC), also referred to as bone marrow stromal cells, are a common fibroblastic cell population within bone that regulates hematopoiesis, has a robust ability to self-renew, can differentiate into multiple mesenchymal cell lineages, and constitutively produces IL-6 ( 14 , 15).”
BackgroundCaplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“A growing body of evidence demonstrates that stromal cell fibroblasts are influential players in tumor progression and metastasis ( 9 ).”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 3×
“Signal transducer and activator of transcription 3 (STAT3) is one of the primary intracellular targets activated after exposure to IL-6 (18), and STAT3 activation has been connected with enhanced tumor cell growth, survival, and immune evasion in breast cancer (22–24).”
BackgroundInfluentialCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“cancers including multiple myeloma (19), prostate”
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994 · cited 1×
“, C57BL/6, and FVB/N) as described (26) and maintained in RPMI 1640 complete media.”
BackgroundSelf-citationThe role of IL-6 and STAT3 in inflammation and cancer
Hodge, D. R., Hurt, E. M., & Farrar, W. L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.016 · Cited by 950 · cited 1×
“Of interest, the bone marrow microenvironment in postmenopausal women maintains stable levels of IL-6 protein, regardless of systemic estradiol levels (33); therefore, it is possible that the bone marrow microenvironment may represent a more favorable tissue for IL-6-responsive ER -positive tumor cells (32, 34).”
BackgroundChanges in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 914 · cited 3×
“function at menopause, the availability of systemic estradiol dramatically decreases, placing more pressure on a given tissue to maintain estradiol levels through local aromatase activity (38).”
BackgroundStudeny, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., Champlin, R. E., & Andreeff, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh299 · Cited by 842 · cited 1×
“MSC also have the capacity to acquire phenotypic profiles similar to activated fibroblasts and can preferentially engraft within mammary tumor xenografts ( 17 ).”
BackgroundComparative biology of mouse versus human cells: modelling human cancer in mice
Rangarajan, A., & Weinberg, R. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1235 · Cited by 567 · cited 1×
“Our findings also reaffirm the need for cancer biologists to consider that paracrine factors within the tumor microenvironment may not readily cross the species boundary from mice to humans ( 35 ) and that some of these factors may be involved in critical aspects of human cancer pathophysiology.”
BackgroundMoinfar, F., Man, Y., Arnould, L., Bratthauer, G. L., Ratschek, M., & Tavassoli, F. A. (2000) · PubMed · Cited by 403
Significance of interleukin-6 (IL-6) in breast cancer (review)
Knüpfer, H., & Preiß, R. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9328-3 · Cited by 396 · cited 4×
“Although elevated serum levels of IL-6 are known to correlate with disease progression and poor clinical outcome in breast cancer patients (7, 36), the biological mechanism (or mechanisms) that account for these observations are not fully resolved (5).”
BackgroundInfluentialAutocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 334
Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J.-Y. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600956 · Cited by 317 · cited 1×
“Although elevated serum levels of IL-6 are known to correlate with disease progression and poor clinical outcome in breast cancer patients (7, 36), the biological mechanism (or mechanisms) that account for these observations are not fully resolved (5).”
BackgroundOkamoto, M., Lee, C., & Oyasu, R. (1997) · PubMed · Cited by 304
Purohit, A., Newman, S. P., & Reed, M. J. (2002) · Breast Cancer Research · doi:10.1186/bcr425 · Cited by 252 · cited 1×
“It has been suggested that increased systemic IL-6 in postmenopausal women may drive ER -positive tumorigenesis through induction of local breast tissue estradiol synthesis (37), but the strength of this hypothesis on its own is weakened by several experimental and clinical observations.”
BackgroundBennermo, M., Held, C., Stemme, S., Ericsson, C.-G., Silveira, A., Green, F., & Tornvall, P. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.037531 · Cited by 205 · cited 1×
“elevated serum levels of IL-6 (6); it significantly re-”
BackgroundLing, X., & Arlinghaus, R. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2425 · Cited by 201 · cited 2×
“Taken together, our data suggest that IL-6 is necessary and sufficient for enhanced MCF-7 cell growth rates in the presence of hMSC; in conjunction with previous reports that have linked STAT3 activity to more aggressive breast tumor cell behavior (23, 24, 32), Figure 3.”
BackgroundResultThe Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer
Parr, C., Watkins, G., Mansel, R. E., & Jiang, W. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0553-3 · Cited by 198 · cited 1×
“Tumor volumes were calculated by length width measurements twice a week for the times indicated (formula: lw20.512) ( 28 ).”
MethodEstrogen Receptors and Distinct Patterns of Breast Cancer Relapse
Hess, K. R., Pusztai, L., Buzdar, A. U., & Hortobagyi, G. N. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1022166517963 · Cited by 197 · cited 2×
“, estrogen receptor-alpha (ER )-positive) tumors have a much stronger metastatic predilection for bone than their ER -negative counterparts (2, 3).”
BackgroundRoles and Regulation of Stat Family Transcription Factors in Human Breast Cancer
Clevenger, C. V. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63403-7 · Cited by 197 · cited 2×
“Of interest, the bone marrow microenvironment in postmenopausal women maintains stable levels of IL-6 protein, regardless of systemic estradiol levels (33); therefore, it is possible that the bone marrow microenvironment may represent a more favorable tissue for IL-6-responsive ER -positive tumor cells (32, 34).”
BackgroundResultKIM, D., YOO, K., CHOI, K., CHOI, J., CHOI, S., YANG, S., YANG, Y., IM, H., KIM, K., & JUNG, H. (2005) · Cytokine · doi:10.1016/j.cyto.2005.04.004 · Cited by 195 · cited 1×
“Mesenchymal stem cells (MSC), also referred to as bone marrow stromal cells, are a common fibroblastic cell population within bone that regulates hematopoiesis, has a robust ability to self-renew, can differentiate into multiple mesenchymal cell lineages, and constitutively produces IL-6 (14, 15 ).”
BackgroundKurose, K. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1907 · Cited by 191
Kasid, A., Lippman, M. E., Papageorge, A. G., Lowy, D. R., & Gelmann, E. P. (1985) · Science · doi:10.1126/science.4039465 · Cited by 186 · cited 1×
“This observation is consistent with other reports demonstrating that ER -positive MCF-7 cells do not readily form xenografts in immunocompromised mice unless they are supplemented with estrogen tablets, coinjected with fibroblasts in Matrigel BME, or mutant Ras is introduced into MCF-7 cells before injection (30, 31).”
ResultInterleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele, A. M., Martin, A.-M., Mick, R., Gor, P. P., Wray, L., Klein-Cabral, M., Athanasiadis, G., Colligan, T., Stadtmauer, E. A., & Weber, B. (2003) · PubMed · Cited by 155
Noël, A., Pauw-Gillet, M. C. D., Purnell, G., Nusgens, B., LAPIERE, C. H. M., & Foidart, J. M. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.453 · Cited by 143 · cited 1×
“This observation is consistent with other reports demonstrating that ER -positive MCF-7 cells do not readily form xenografts in immunocompromised mice unless they are supplemented with estrogen tablets, coinjected with fibroblasts in Matrigel BME, or mutant Ras is introduced into MCF-7 cells before injection (30, 31).”
ResultFactors regulating the growth of metastatic cancer in bone.
Boyce, B. F., Yoneda, T., & Guise, T. A. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060333 · Cited by 143 · cited 1×
“with breast cancer (1), and clinical studies have demonstrated that hormone-responsive (i.”
BackgroundJames, J. J., Evans, A. J., Pinder, S. E., Gutteridge, E., Cheung, K., Chan, S. Y. T., & Robertson, J. F. R. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601198 · Cited by 138 · cited 2×
“, estrogen receptor-alpha (ER )-positive) tumors have a much stronger metastatic predilection for bone than their ER -negative counterparts (2, 3).”
BackgroundCat, B., Stuhlmann, D., Steinbrenner, H., Alili, L., Holtkötter, O., Sies, H., & Brenneisen, P. (2006) · Journal of Cell Science · doi:10.1242/jcs.03011 · Cited by 132 · cited 1×
“tion that activated fibroblasts (8) produce elevated”
The shape of age–incidence curves of female breast cancer by hormone-receptor status
Yasui, Y., & Potter, J. D. (1999) · Cancer Causes & Control · doi:10.1023/a:1008970121595 · Cited by 128 · cited 1×
“And finally, concurrent with declining systemic estradiol (and increasing IL-6) at menopause (38), the incidence of ER -positive breast cancer dramatically increases, suggesting that other factors, possibly IL-6, may contribute to ER positive tumor growth and metastasis (39).”
BackgroundSasser, A. K., Mundy-Bosse, B. L., Smith, K. M., Studebaker, A. W., Axel, A. E., Haidet, A. M., Fernández, S., & Hall, B. M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.012 · Cited by 121 · cited 2×
“As described earlier (27), hMSC enhanced MCF-7 growth in excess of 2-fold over baseline growth in 8 days.”
BackgroundMethodSelf-citationAnderson, W. F., Jatoi, I., & Devesa, S. S. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-3777-3 · Cited by 117 · cited 1×
“Although hormoneresponsive breast cancer patients tend to have a more favorable clinical prognosis than hormone unresponsive patients (4), those presenting with bone metastasis or increased serum interleukin-6 (IL-6) levels, regardless of ER status, face high mortality rates (5).”
Backgroundvan Dam, M., Müllberg, J., Schooltink, H., Stoyan, T., Brakenhoff, J. P. J., Graeve, L., Heinrich, P. C., & Rose‐John, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82467-x · Cited by 113 · cited 2×
“It has been known for some time that the human IL-6 receptor does not recognize murine IL-6 (29).”
BackgroundInterleukin‐6 functions as an autocrine growth factor in a cholangiocarcinoma cell line
Okada, K., Shimizu, Y., Nambu, S., Higuchi, K., & Watanabe, A. (1994) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1994.tb01275.x · Cited by 92 · cited 1×
“cancer (20), and cholangiocarcinoma (21).”
Selander, K. S., Li, L., Watson, L., Merrell, M. A., Dahmen, H., Heinrich, P. C., Müller‐Newen, G., & Harris, K. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2516 · Cited by 92 · cited 2×
“Taken together, our data suggest that IL-6 is necessary and sufficient for enhanced MCF-7 cell growth rates in the presence of hMSC; in conjunction with previous reports that have linked STAT3 activity to more aggressive breast tumor cell behavior (23, 24, 32), Figure 3.”
BackgroundResultKassem, M. S., Khosla, S., Spelsberg, T. C., & Riggs, B. L. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.2.8636260 · Cited by 61
Regulation of Lymphoid and Myeloid Leukemic Cell Survival: Role of Stromal Cell Adhesion Molecules
Hall, B. M., & Gibson, L. F. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000139620 · Cited by 27
Self-citation
Research works printed but not linked: 1
- 10.1210/jc.81.2.513 · doi:10.1210/jc.81.2.513
Cited by
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
“For example, interleukin-6 (IL6) is upregulated in epithelial cancers such as breast and prostate (Sasser et al., 2007; Wegiel et al., 2008).”
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
“For example, although IL-6 secretion occurs in ER breast cancer cells, no IL-6 expression is detected in various ER+ breast cancer cell lines (Sasser et al., 2007) or in A375 melanoma.”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Self-citationInterleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
“IL-6 is a pleiotropic cytokine that participates in acute inflammation as the major inducer of C-reactive protein, plays a central role in hematopoiesis (Kishimoto, 2006), and enhances proliferation of breast cancer cells (Sasser et al., 2007b).”
BackgroundMethodResultInfluentialSelf-citationConstitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
Metadata
- Authors
- Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M.
- Affiliations
- The Ohio State University (US)
- Center for Childhood Cancer Children's Research Institute Columbus Ohio USA
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-06-22
- Volume
- 21
- Issue
- 13
- Pages
- 3763-3770
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1973576115
- Cited by
- 222
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 14 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 13 · 2015: 14 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Elsa U. Pardee Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- interleukin-6, estrogen receptor alpha, breast cancer, mesenchymal stem cells, STAT3 phosphorylation, bone metastasis, paracrine signaling, autocrine signaling, tumor growth, MCF-7 cells, IL-6 receptor
- MeSH terms
- Breast Neoplasms, Humans, Interleukin-6, Cell Line, Tumor, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.